1,540 Shares in Becton, Dickinson and Company (NYSE:BDX) Acquired by V2 Financial group LLC

V2 Financial group LLC bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 1,540 shares of the medical instruments supplier’s stock, valued at approximately $349,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Sound Income Strategies LLC boosted its holdings in Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 44 shares during the last quarter. Tompkins Financial Corp boosted its stake in shares of Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 46 shares during the last quarter. Birch Capital Management LLC grew its holdings in shares of Becton, Dickinson and Company by 0.4% in the third quarter. Birch Capital Management LLC now owns 11,773 shares of the medical instruments supplier’s stock worth $2,838,000 after acquiring an additional 48 shares during the period. Radnor Capital Management LLC increased its position in Becton, Dickinson and Company by 1.7% during the third quarter. Radnor Capital Management LLC now owns 2,937 shares of the medical instruments supplier’s stock valued at $708,000 after acquiring an additional 48 shares during the last quarter. Finally, Wesbanco Bank Inc. lifted its holdings in Becton, Dickinson and Company by 1.9% in the fourth quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier’s stock valued at $580,000 after acquiring an additional 48 shares during the period. Institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on BDX shares. Piper Sandler boosted their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $283.00.

Becton, Dickinson and Company Stock Up 1.3 %

BDX stock opened at $230.22 on Monday. The business’s 50-day moving average price is $232.07 and its 200-day moving average price is $234.04. The stock has a market cap of $66.77 billion, a P/E ratio of 38.24, a PEG ratio of 1.65 and a beta of 0.40. The company has a quick ratio of 0.74, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. On average, equities research analysts forecast that Becton, Dickinson and Company will post 14.41 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be issued a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 1.81%. Becton, Dickinson and Company’s dividend payout ratio is presently 69.10%.

Becton, Dickinson and Company declared that its Board of Directors has authorized a share buyback plan on Tuesday, January 28th that permits the company to buyback 10,000,000 shares. This buyback authorization permits the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

Insider Activity

In other news, EVP Michael David Garrison sold 2,838 shares of the business’s stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $223.33, for a total value of $633,810.54. Following the transaction, the executive vice president now owns 6,141 shares of the company’s stock, valued at approximately $1,371,469.53. The trade was a 31.61 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Roland Goette sold 638 shares of the firm’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $219.03, for a total transaction of $139,741.14. Following the transaction, the executive vice president now directly owns 14,217 shares of the company’s stock, valued at $3,113,949.51. The trade was a 4.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 9,844 shares of company stock worth $2,210,716 over the last ninety days. Corporate insiders own 0.36% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.